ELIZABETH TERRY: Open Payments
NPI 1922524644 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,618 in 144 payments from 11 companies in 2025. Trend: 2023 $2,356 · 2024 $2,424 · 2025 $4,618
Food & beverage: $4,168Speaker / faculty: $450
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 70 | $2,425 |
| Madrigal Pharmaceuticals | 27 | $816 |
| GENZYME CORPORATION | 14 | $465 |
| Gilead Sciences, Inc. | 13 | $211 |
| Janssen Scientific Affairs, LLC | 2 | $201 |
| Novo Nordisk Inc | 4 | $173 |
| Ardelyx, Inc. | 8 | $154 |
| Amgen Inc. | 1 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| EVOKE PHARMA, INC. | 1 | $16 |
Products named: RINVOQ, REZDIFFRA, SKYRIZI, DUPIXENT, CREON, LINZESS, TREMFYA, IBSRELA.
Industry payments across TX — which companies pay providers there.
